Date: May 31, 2004

FINANCIAL EXPRESS

Southern Online Bio Technologies Limited SBT (CIN: L72900TG1998PLC030463)

RegdOffice : A3, 3rd Floor, Office Block Samrat Complex, Salfabad, Hyderabad-500 004, Telangana, India Phone : +91 40 2324 1999, +91 40 4434 1999, Fax : +91 40 2324 1444, E-Mail: info@sol.net.in Corporate Office: Flat No. 682, 6th Floor, Swarna Jayanthi Complex, Beside Maltrivanam, Ameerpet, Hyderabad, 500638, Telangana, India Phone: 045-23746601

Extract of Audited Financial Results for the Quarter and Financial Year ended 31" March, 2024

	Standalone (Rs. Lakhs)							
Particulars		Quarter Ended	Year Ended					
Particulars	11.05.2024	81.12.2023	31.05.2023	31.03.3024	31.05.2021			
	(Audited)	(Unwudsted)	(Audited)	(Audited)	(Audited)			
Tutal Income from Operations	1,599.02	1,406.47	496.28	6,732.85	1,497.8			
Not Profit / (Loss) for the period (Before Tax, Exceptional and/or extraordinary items)	(130.68)	(212.71)	(330.41)	(724.30)	(\$15.48			
Net Profit / (Loss) for the period before tax (After Exceptional and/or extraordinary items)	(130.68)	(212.71)	(330.41)	(724.30)	(515.48			
Net Profit / (Loss) for the period after tax (after Exceptional and/or extraordinary items)	(330.68)	(212.71)	(330.41)	(724.30)	(535.48			
Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tas) and Other Comprehensive Income (after tas)]	(131.67)	(212.71)	(829.13)	(725.49)	(535.59			
Paid up Equity Share Capital	4,500.00	4,500.00	4,500.00	4,500.00	4,500.0			
Reserves (excluding Revolution Reserve)	(727.48)	595-82	(1.99)	(727.48)	(1.99			
Ret worth	3,772.52	5,095-82	4,496.01	1,772.52	4,496.0			
Earnings Per Share (of Rs. /- each) (for continuing and discontinued operations)								
Basic (Rs)	(0.29)	(0.47)	(0.73)	(1.61)	(1.15			
Diluted (Rs)	(0.29)	(0.47)	(0.73)	(1.61)	(1.15			

The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the LODR Regulations. The Full format of the Quarterly / Annual Financial Results are available on the websites of the BSE Ltd (www.bseindia.com) and the Company. (www.sol.net.in)

Dr Devaleh Psgidget Managing Director **SALGUTI INDUSTRIES LIMITED** CIN: L25209TG1984PLC005048 8-2-334/18, Road No 3, Banjarahills, Hyderabad - 500034. www.salguti.com. **EXTRACT OF AUDITED FINANCIAL RESULTS FOR** (Rs in Lakhs THE 4TH QUARTER AND YEAR ENDED 31.03.2024 except for EPS)

SI No	PARTICULARS	Quarter Ended 31-03- 2024 Audited	Quarter Ended 31-03- 2023 Audited	Year Ended 31-03- 2024 Audited	Year Ended 31-03- 2023 Audited
1	Total income from operations (net)	2,092.92	2,207.23	8,693.56	10,158.16
2	Net Profit / (Loss) for the period (before Tax,				
	Exceptional and/or Extraordinary items)	(31.59)	(2.00)	(41.66)	5.13
3	Net Profit / (Loss) for the period before tax (after				
	Exceptional and/or Extraordinary items)	(31.59)	(2.00)	(41.66)	5.13
4	Net Profit / (Loss) for the period after tax (after				
	Exceptional and/or Extraordinary items)	(18.85)	(28.21)	(11.59)	0.87
5	Total Comprehensive Income for the period				
	[Comprising Profit / (Loss) for the period (after tax)				
	and Other Comprehensive Income (after tax)]	(18.85)	(28.21)	(11.59)	0.87
6	Equity Share Capital (Face Value INR 10/- each)	753.67	753.67	753.67	753.67
7	Earnings Per Share (for continuing and				
	discontinued operations) (of INR 10/- each)				
	Basic	(0.25)	(0.37)	(0.15)	0.01
	Diluted	(0.25)	(0.37)	(0.15)	0.01

The above results have been reviewed by the Audit Committee at its meeting held on and approved by the Board of Directors at its meeting held on even date.

The figures of the previous year/periods have been re-grouped/re-classifed, whenever necessary. The above is an extract of the detailed format of financial results for the Quarter & Year ended 31st March, 2024, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarter & Year ended Financial Results are available on the Exchange websites i.e., www.msei.in& www.bseindia.com and on the company's website www.salguti.com

> FOR SALGUTI INDUSTRIES LIMITED Rajitha Reddy Salguti

For Southern Online Bio Technologies Limited

Place: Hyderabad Date: 30-05-2024 Whole-time director Din: 0051603

BHUDEVI INFRA PROJECTS LIMITED (Formerly Known as AARV Infratel Limited)

Registered Office: 1-8-303/48/13/202, 302, 3rd Floor, Arya One, Sindhi Colony, S.P. Road, Secunderabad, Hyderabad, Secunderabad, Telangana, India, 500003

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH 2024

	Regulation 47(1) (b) of the SEBI (LODR) Regulations, 2015 (R							
Sr. No.	PARTICULARS	Quarter ending 31-03-2024 Audited	Quarter ending 31-03-2023 Un-Audited	Year ending 31-03-2024 Audited	Year ending 31-03-2023 Audited			
1	Total Income from Operations	205.30	-	368.43	62.30			
2	Net Profit / (Loss) for the period (before Tax,							
	Exceptional and/or Extraordinary items)	220.98	(14.65)	121.71	32.11			
3	Net Profit / (Loss) for the period before tax							
	(after Exceptional and/or Extraordinary items)	220.98	(14.65)	121.71	32.11			
4	Net Profit / (Loss) for the period after tax							
	(after Exceptional and/or Extraordinary items)	190.82	(14.65)	91.27	32.11			
5	Total Comprehensive Income for the period							
	[Comprising Profit / (Loss) for the period							
	(after tax) and Other Comprehensive							
	Income (after tax)]	190.82	(14.65)	91.27	32.11			
6	Equity Share Capital	510	510	510	510			
7	Reserves (excluding Revaluation Reserve)							
	as shown in the Audited Balance Sheet of the							
	previous year	-	-	(436.98)	(528.23)			
8	Earnings Per Share (of Rs. 10/- each)							
	(for continuing and discontinued operations) - 1. Basic:	4.16	(0.33)	1.99	0.70			
	2. Diluted:	4.16	(0.32) (0.32)	1.99	0.70			
		1	` /	110	1			

1. The Financial results for the Quarter and Year Ended March 31, 2024 were reviewed by the Audit Committee and taken on record and approved by the Board of Directors at their meeting held on May 30, 2024. 2. The above is an extract of the detailed format of Quarterly /Annual Financial Results filed with the Stock Exchanges under regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the Stock Exchange website. i.e. BSE Limited at www.bseindia.com and company website i.e.www.bhudeviprojects.com/

3. The Financial Results include the results for the Quarter Ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial Year and the published unaudited year to date figures up to the third quarter of the current Financial Year which are subject to limited review by the statutory auditors of the company. For Bhudevi Infra Projects Limited (Formerly Known as AARV Infratel Limited)

sd/- Bhasker K Bhatt Place: Hyderabad Managing Director Date :30-05-2024 DIN: 09463033

G.R. CABLES LIMITED

CIN:L31300TG1992PLC013772 Regd. Office: #6-2-966/2, Madhava Apartments, Flat No. 301, Hill Colony, Khairathabad, Hyderabad - 500004. email: grcablesltd@gmail.com

STATEMENT OF STANDALONE FINANCIALS RESULTS FOR THEAII amounts in Indian Rupees

Lakhs, except share data

DIN #06451862

Consolidated

Namita Sanjay Banka

Managing Director

DIN: 05017358

1.07

Place: Mumbai

Integrated

Limited 1

Thermoplastics

QUARTER AND YEAR ENDED 31ST MARCH, 2024

SI.	DARTIOU LARC	2		ANDALON	E	
No.	PARTICULARS	Quarter ended 31-03-2024 Audited	Quarter ended 31-12-2023 UnAudited		Year ended 31-03-2024 Audited	Year ended 31-03-2023 Audited
1 2	Revenue from operations Net Profit / (Loss) for the period (before Tax, Exceptional and/or	(50.50)	0.10	(04.54)	3.43	(00.00)
3	Extraordinary items) Net Profit / (Loss) for the period before Tax, (after Exceptional	(53.50)	(7.48)	(21.51)	(59.65)	(23.28)
4	and/or Extraordinary items) Net Profit / (Loss) for the period after Tax, after Exceptional and/or	(53.50)	(7.48)	(21.51)	(23.28)	(23.28)
5	Extraordinary items) Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(53.50)	(7.48)	(21.51)	(59.65)	(23.28)
6 7	Equity Share Capital Reserves (excluding Revaluation Reserve) as shown in the Audited	861.53	2,889.49	2,889.49	2,889.49	2,889.49
8	Balance Sheet of the previous year Earning per share (before Extraordinary items) (Face Value of Rs.10/-each)				(59.65)	(4,028.47)
9	1) Basic 2) Diluted Earning per share (after Extraordinary items) (Face Value of Rs.10/-each)					(0.081) (0.081)
	1) Basic 2) Diluted	(0.220) (0.220)	(0.030) (0.030)	(0.070) (0.070)	(0.240) (0.240)	

The above is an extract of the detailed format of the financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. The full format of Unaudited financials results are available on the Stock Exchange websites (URL of the filings: www.bseindia.com) . The above results have been reviewed and recommended by the Audit Committee and approved

by the Board of Directors of the Company at their meeting held on May 30, 2024 These results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the companies Act 2013 and other recognized accounting pratices and policies to the extent applicable. 3. The figures for the previous period/year have been regrouped/reclassified, wherever necessary.

I. The Company operates in one segment. For G.R. Cables Limited

Nitin Kumar Mathur Place: Hyderabad Whole-time Director

BANKA BIOLOO LIMITED

Date: 30-05-2024

R/o: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

C/o: Prestige Phoenix, 5 th floor, 1405, Uma Nagar, Begumpet, Hyderabad - 500016 +91 8688825013• info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811 EXTRACT OF AUDITED FINANCIAL RESULTS (BOTH STANDALONE AND

CONSOLIDATED) FOR THE QUARTER AND YEAR ENDED 31.03.2024 (RS. IN LACS)

Standalone

Quarter Year Year Quarter Year Year

PARTICULARS	Quarter Ended 31-03-2024 Audited	Year Ended 31-03-2024 Audited	Year Ended 31-03-2023 Audited	Quarter Ended 31-03-2024 Audited	Year Ended 31-03-2024 Audited	Year Ended 31-03-2023 Audited
Total income	1675.46	5074.11	4295.56	1643.30	5049.06	4305.09
Net Profit (before Tax, Exceptional.						
and/or Extraordinary items)	15.50	41.42	414.78	(9.39)	(56.33)	362.41
Net Profit before tax (after Exceptional						
and/or Extraordinary items)	15.50	41.42	414.78	(9.39)	(56.33)	362.41
Net Profit after tax (after Exceptional						
and/or Extraordinary items)	2.29	32.65	307.64	(24.68)	(67.11)	253.89
Total Comprehensive Income [Comprising Profit after tax and Other						
Comprehensive Income (after tax)]	17.89	48.25	313.44	(9.07)	(51.50)	259.70
Paid up Equity Share Capital						
(Rs.10 per Equity Share)	1084.66	1084.66	1084.66	1084.66	1084.66	1084.66
Reserves (excluding Revaluation						
Reserve) as shown in the Balance Sheet)	3035.06	3035.06	2974.28	2887.33	2887.33	2925.24
Earnings Per Share (Not Annualised for quarter)						
a) Basic	0.02	0.30	2.84	(0.22)	(0.60)	2.39
b) Diluted	0.02	0.30	2.84	(0.22)	(0.59)	2.39

1) The above standalone and consolidated financial results are reviewed and recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 30 May 2024.) The above is an extract of the detailed format of Financial Results filed with National Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Annual Financial Results is available on company's website at www.bankabio.com and the stock exchange's website, www.nseindia.com For Banka BioLoo Limited

Place: Hvderabad

ARUNJYOTI BIO VENTURES LIMITED

604B, Jain Sadhguru Image Garden Park, Madhapur, Hyderabad-500082 CIN NO: L01400TG1986PLC062463 Extract of Audited financial results for the Quarter and Year Ended March 31,2024 (All amounts are in INR Lakh except share data or unless otherwise stated) Quarter Ended Year Ended Quarter Ended Year Ended Year Ende **Particulars** Mar 31, 2023 Mar 31, 2024 Mar 31, 2023 Mar 31, 2024 Dec 31, 2023 (Audited) (Audited) (Audited) (Audited) (Un-Audited) 1 Total income 2,043.15 173.53 16.84 26.63 [40.92] (129.85) 43.97 2 Net Profit (before Tax, Exceptional items) 3 Net Profit before tax (after Exceptiona items) 140.925 43.97 16.84 [129.85] 26.63 4 Net Profit after tax (after Exceptional items) 16.84 22.18 126.07 [28.06] (34.89) Total Comprehensive Income (Comprising Profit after tax [28.06](34.89) 126.07 16.84 22.18 and Other Comprehensive Income (after tax)) Paid up Equity Share Capital (Face Value 207.09 207.09 207.09 207.09 207:09 Rs.10'- Per Equity Share) 7 Reserves (excluding Revaluation Reserve as shown (30.43) 4.46 4.46 4.46 4.46 in the Audited Balance Sheet of previous year ended) 8 Earnings Per Share (of Rs.10/- each) (Not Annualised for guarters) 1.07 a) Basic 6.09 $\{1.35\}$ 0.81 (1.68)

The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on May 30,2024.

NOTE: The above is an extract of the detailed format of Quarterly Financial Results field with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Bombay stock exchange website, the National stock exchange website and on the company's website.

[1.35]

0.81

For Arunjyoti Bio Ventures Limited

Place: Hyderabad Date: 30" May 2024

b) Diluted

Date: 31-05-2024

Pabbathi Badari Narayana Murthy Wholetime Director DIN - 01445523

(1.68)



CES LIMITED

Regd. Office: 7th Floor, Tower A, Ramky Selenium, Nanakramguda, Financial District, Gachibowli, HYDERABAD - 500 032

Phone No. 040 42421122 Fax No. 040 40102456

(Rs. In Lakhs)

AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2024

	Particulars		C	onsolidate	d		Standalone				
SL	Particulars	Quarter ended			Year ended		Quarter ended			Year ended	
No.		31.03.2024	31.12.2023	31.03.2023	023 31.03.2024	31.03.2023	31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		Audited	Un-Audited	Audited	Audited	Audited	Audited	Un-Audited	Audited	Audited	Audited
1	Total Income from Operations	11,648.57	11,861.56	10,345.29	47,215.46	43,268,26	6,017.12	5,785.06	4,916.05	23,062.85	20,901.92
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items #)	571.19	1,061,36	(732.00)	3,738.94	2,852.03	625.59	149.51	(137.16)	1,079.51	1,281.04
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items #)	571.19	1,061.36	(732.00)	3,738.94	2,852.03	625.59	149.51	(137.16)	1,079.51	1,281.04
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items #)	540.70	733.94	(369.27)	2,648.11	1,951.43	512.60	95.44	62.48	753.15	894.96
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	410.45	897.31	(192.83)	2,793.17	2,460.89	346.15	223.56	164.28	788.21	1,340.56
6	Equity Share Capital	364.00	364.00	364.00	364.00	364.00	364.00	364.00	364,00	364.00	364.00
7	Earnings Per Share (of Rs. 10 /- each) (for continuing and discontinued operations) 1. Basic 2. Diluted	1.49 1.49	2.02 2.02	(1.01) (1.01)	7.28 7.28	5.36 5.36	1.41 1.41	0.26 0.26	0.17 0.17	2.07 2.07	2.46 2.46

Note: The above is an extract of detailed format of Quarterly / Year end Financial results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing and other Disclosure Requirements) Regulations 2015. The full format of the Quarterly / year end Financial Results are available on Stock Exchange Website: www.bseindia.com

Place: Hyderabad, Dated: 30th May, 2024 Shri Mohana Rao Kancharla While-Time Director

For CES Limited.

KOBO BIOTECH LIMITED

Regd. Office: Plot No. 121A/1, Western Hills, Addagutta Society, Opp. JNTU, Kukatpally, Hyderabad - 500072 Corp. Office: Unit 101/104, Hyde Park, Saki Vihar Road, Andheri (E), Mumbai - 400 072

	(Amount Rs in La								
			Quarter ended	- 19	Year Er	nded			
Sr No	Particulars	31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Audited)	31.03.2024 (Audited)	31.03.2023 (Audited)			
1	Total Income from Operation	0.00	0.00	0.00	0.00	0.00			
2	Net Profit / (Loss) for the period before Tax and Exceptional items	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)			
3	Net Profit / (Loss) for the period before Tax	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)			
4	Net Profit / (Loss) for the period after Tax	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)			
5	Total Comprehensive Income for the period	(125.62)	(123.13)	(179.34)	(492.88)	(555.34)			
6	Equity Share Capital	(*	*3	· ·	2,382.50	2,382.50			
7	Reserves (excluding Revaluation Reserve)	11.0	55	*	(15,673.53)	(15,180.65)			
8	Earnings Per Share 1. Basic 2. Diluted	(0.53) (0.53)	(0.52) (0.52)	(0.75) (0.75)	(2.07) (2.07)	(2.33) (2.33)			

The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the Stock Exchange(s) and the website of the Company at www.kobobiotech.com By order of the Board For Kobo Biotech Limited

INGEGRATED THERMOPLASTICS LTD

CIN: L25209TG1994PLC016939

Sy. No. 375, Mancharabad (V), Toopran (M), Medak Dist. Telangana-502334

Date: 31/05/2024 **Ajit Kamath** Director

05 10 12	Quarter Ended	Year to date figures for current period ended	(Rs. in Lakhs Year ended	
Particulars	31.03.2024	31.03.2024	31.03.2023	
	(Audited)	(Audited)	(Audited)	
Total Income from Operations	130.72	368.28	768.15	
Total Expenses	515.77	1355.28	1745.41	
Net Profit/(Loss)for the period (before Tax, Exceptional and/or extraordinary items)	(385.05)	(987.00)	(977.26)	
Net Profit / (Loss) for the period after tax (after Exceptional and/or extraordinary items)	(401.45)	(1003.41)	(997.24)	
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]				
Paid up Equity Share Capital(Face Value per share is Rs. 10 each)	628.89	628.89	628.89	
Reserves (Excluding Revaluation Reserve)				
Earnings Per Share(of Rs.10/- each)				
a. Before Extraordinary items- Basic & Diluted	(6.38)	(15.96)	(15.86)	
b. After Extraordinary items- Basic & Diluted	(6.38)	(15.96)	(15.86)	

1. The above results were taken on record at the meeting of the Board of the Directors of the Company held on 30" May, 2024. The above results have been reviewed by the Audit Committee and approved by the Board of Directors. 2. The Full format of the financial Result for the Fourth Quarter and Year Ended 31" March, 2024 and Explanatory Notes are available on

the stock exchange website at www.bseindia.com and on the company's website at www.integratedthermo.com For Integrated Thermoplastics Limited

Place: Mumbai Date: 30th May, 2024 Tel.: 9848019282 Vydana Venkata Rao

ORTIN LABORATORIES LIMITED

Regd.off: My Fair Gardens, 8-2-682/3/A & 3B, Flat No 201, 2nd Floor, Road No 12, Banjara Hills, Hyderabad-500034, Telangana, India URL: https://www.ortinlabsindia.com/, email:info@ortinlabsindia.com

Extract of audited financial results of the Company for the guarter and year ended 31st March 2024 prepared in compliance with Indian Accounting Standards Amounts in Lakhs

Quarter Ended Year Ended 31.03.2024 31.12.2023 31.03.2023 31.03.2024 31.03.2023 S.No **Particulars** Audited Unaudited Audited Audited Audited 30.90 13.68 148.57 228.49 606.23 Total Income from Operations 2 -280.63 Net Profit /(Loss) for the period -317.80-18.15-707.41(8.83)(before tax, Exceptional and /or extraordinary items) -317.80-280.74-20.82-707.52 (11.05)Net Profit /(Loss) for the period before tax, (after Exceptional and /or extraordinary items) Net Profit /(Loss) for the period -414.48 -279.18-20.35-804.10 -9.36after tax, (after Exceptional and /or extraordinary items) Total Comprehensive Income for -414.48 -279.18-20.35-804.10-9.36the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] 813.14 **Equity Share Capital** 813,14 813,14 813.14 813.14 Earnings Per Share (of Rs.10 each)

 The above is an extract of the detailed format of Standalone audited Financial Results for the guarter and year ended 31st March, 2024. The same have been reviewed by the Audit Committee and were taken on record by the Board of Directors in their respective meetings held on 30.05.2024 The Statutory Auditors of the company have carried out an Audit of the aforesaid results.

-5.10

-3.43

-3.43

-0.25

-0.25

-9.89

-9.89

-0.12

-0.12

The above is an extract of the detailed audited Financial Results for the quarter and year ended 31st March, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The audited Financial Results in full format are available on the website of the Stock Exchanges (www.bseindia.com and www.nseindia.com) and the Company (https://www.ortinlabsindia.com/) For ORTIN LABORATORIES LIMITED Place: Hyderabad

MURALI KRISHNA MURTHY SANKA Date:30.05.2024 **Managing Director**



Basic in Rs.

Diluted in Rs.

EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED 31.03.2024

(Rs.in Lakhs) Standalone Quarter Ended Year Ended **Particulars** 31.03.2024 31.12.2023 31.03.2023 31.03.2024 31.03.2023 Audited Un-Audited Audited Audited Audited 1,056.52 917.83 818.68 3968.45 Total income 3,100.52 Net Profit (403.81) (1,390.87) (283.45)(349.46)(1,063.83)(before Tax, Exceptional and/or Extraordinary items) Net Profit before tax (258.71)(354.60)(409.24) (1,387.17) (1,137.27) (after Exceptional and/or Extraordinary items) (377.63)(429.08)(347.93) (1,157.10) Net Profit after tax (after Exceptional and/or Extraordinary items) Total Comprehensive Income [Comprising Profit after tax 808.69 (377.63)(429.08)(340.82)(1,157.10)and Other Comprehensive Income (after tax)] Paid up Equity Share Capital (Rs.10/- Per Equity Share) 3,348.35 3,348.35 1,420.13 3,348.35 1,420.13 Reserves (excluding Revaluation Reserve) as shown in -5360.59 -6040.13 the Balance Sheet of previous year Earnings Per Share (of Rs.10/- each) (Not Annualised): 2.55 a) Basic (1.12)(3.02)(1.09)(8.15)b) Diluted 2.44 (1.07)(3.02)(1.04)(8.15)

 The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at its meeting held on May 30 2024.

2. The above is an extract of the detailed format of Quarterly Financial Results field with the Stock Exchange under Regulations 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on company's website at https://www.oxygentapharma.com/ and the stock exchange's website, www.

bseindia.com. 3. The Financial Results include the results for the Quarter Ended March 31, 2024 being the balancing figure between the audited figures in respect of the full financial Year and the published unaudited year to date figures up to the third quarter of the current Financial Year which are subject to limited review by the statutory auditors of the company.

By and on behalf of the Board of Directors of Oxygenta Pharmaceutical Limited

Sai Sudhakar Vankineni Managing Director Place : Hyderabad Date : 30-05-2024 DIN: 00733001

financialexp.epapr.in HYDERARAD